Sitryx announces partner Lilly exercises option to SIT-011 for chronic autoimmune and inflammatory diseases Lilly exercises option to an exclusive worldwide license to develop and commercialize SIT-011, a Phase 1 ready immunometabolism-targeting therapy for chronic autoimmune and inflammatory...